AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29505773 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate and ethinyl estradiol
Number of subjects: 266
Study 29505773 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel implant
Number of subjects: 266
Study 29505773 — intervention group
Group type: EXPERIMENTAL
Intervention: Etonogestrel implant
Number of subjects: 266
Study 29505773 — intervention group
Group type: COMPARATOR
Intervention: Hormonal contraceptive methods (overall)
Number of subjects: 266
Study 27055427 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized N-acetylcysteine (NAC), administered starting within 12 hours of mechanical ventilation, once every 8 hours until stopping mechanical ventilation.
Number of subjects: 117
Study 27055427 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized N-acetylcysteine (NAC)
Number of subjects: 117
Study 27055427 — intervention group
Group type: COMPARATOR
Intervention: Control group (no NAC treatment)
Number of subjects: 117
Study 24361248 — intervention group
Group type: EXPERIMENTAL
Intervention: Amrubicin (40-45 mg/m² for ages 70-74; 40 mg/m² for ages ≥ 75) intravenously on days 1-3 every 3 weeks for 4-6 cycles
Number of subjects: 62
Study 24361248 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin (AUC 5 on day 1) and Etoposide (80 mg/m² on days 1-3) every 3 weeks for 4-6 cycles
Number of subjects: 62
Study 22983988 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 245
Study 19900054 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic antireflux surgery (LARS) in Group I (2000)
Number of subjects: 236
Study 19900054 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic antireflux surgery (LARS) in Group II (1995-96)
Number of subjects: 236
Study 18455086 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride treatment
Number of subjects: 0
Study 16387895 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-rich beverages
Number of subjects: 30
Study 16387895 — intervention group
Group type: COMPARATOR
Intervention: Control (fasted patients)
Number of subjects: 30
Study 15570922 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored CPT-11 + TS-1
Number of subjects: 0
Study 15570922 — intervention group
Group type: COMPARATOR
Intervention: TS-1
Number of subjects: 0
Study 10898337 — intervention group
Group type: COMPARATOR
Intervention: Samarium 153 lexidronam at 1.0 mCi/kg
Number of subjects: 0
Study 10898337 — intervention group
Group type: COMPARATOR
Intervention: Samarium 153 lexidronam at 0.5 mCi/kg
Number of subjects: 0
Study 10898337 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9311544 — intervention group
Group type: EXPERIMENTAL
Intervention: Manganese-exposed workers
Number of subjects: 35
Study 9311544 — intervention group
Group type: COMPARATOR
Intervention: C
Number of subjects: 35
Study 7688774 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin 0.025% cream
Number of subjects: 197
Study 7688774 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 197
Study 3756312 — intervention group
Group type: EXPERIMENTAL
Intervention: Bestatin treatment (daily oral administration)
Number of subjects: 0
Study 3756312 — intervention group
Group type: COMPARATOR
Intervention: Control group (irradiated patients who did not receive Bestatin)
Number of subjects: 0
Study 31820219 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Placement and Support (IPS)
Number of subjects: 146
Study 31820219 — intervention group
Group type: COMPARATOR
Intervention: Traditional vocational rehabilitation
Number of subjects: 146
Study 31099133 — intervention group
Group type: EXPERIMENTAL
Intervention: Promote Children's Growth and Development (PCGD) intervention for 14 weeks
Number of subjects: 144
Study 31099133 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 144
Study 28938325 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexpanthenol-vitamin A (Nazalnem) ointment applied to silastic splints
Number of subjects: 60
Study 28938325 — intervention group
Group type: COMPARATOR
Intervention: Vaseline applied to silastic splints (Control)
Number of subjects: 60
Study 25874578 — intervention group
Group type: EXPERIMENTAL
Intervention: GEn 600 mg
Number of subjects: 671
Study 25874578 — intervention group
Group type: EXPERIMENTAL
Intervention: GEn 1200 mg
Number of subjects: 671
Study 25874578 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 671
Study 25874578 — intervention group
Group type: EXPERIMENTAL
Intervention: GEn 600 mg and 1200 mg
Number of subjects: 671
Study 23797810 — intervention group
Group type: EXPERIMENTAL
Intervention: Laminin‐411, laminin‐511, and laminin‐521
Number of subjects: 0
Study 23797810 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrin α6β1
Number of subjects: 0
Study 23797810 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrin α6β1-deficient mice
Number of subjects: 0
Study 23797810 — intervention group
Group type: COMPARATOR
Intervention: Control group (wild-type mice)
Number of subjects: 0
Study 20820174 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-loss diet (WL)
Number of subjects: 34
Study 20820174 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-loss diet plus resistance training (WL+RT)
Number of subjects: 34
Study 20820174 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 34
Study 19772448 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Options + AIR insulin
Number of subjects: 1021
Study 19772448 — intervention group
Group type: COMPARATOR
Intervention: Standard Options
Number of subjects: 1021
Study 17425817 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 0.2 mg mL-1 with PCA morphine
Number of subjects: 160
Study 17425817 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ondansetron)
Number of subjects: 160
Study 15251380 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 246
Study 15251380 — intervention group
Group type: COMPARATOR
Intervention: No statin therapy
Number of subjects: 246
Study 11735012 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasogastric tubes (NTs)
Number of subjects: 110
Study 11735012 — intervention group
Group type: COMPARATOR
Intervention: Gastrostomy tubes (GTs)
Number of subjects: 110
Study 11735012 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 110
Study 9408725 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental arm of randomized consent design
Number of subjects: 0
Study 9408725 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment arm
Number of subjects: 0
Study 8488909 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine G
Number of subjects: 32
Study 8488909 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine A
Number of subjects: 32
Study 3732088 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium-conserving diuretic (amiloride)
Number of subjects: 0
Study 3732088 — intervention group
Group type: COMPARATOR
Intervention: Potassium-losing diuretic (chlorthalidone)
Number of subjects: 0
Study 31058784 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 cm H2O positive end-expiratory pressure
Number of subjects: 40
Study 31058784 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy control
Number of subjects: 40
Study 28159703 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for insomnia (CBT-I)
Number of subjects: 200
Study 28159703 — intervention group
Group type: COMPARATOR
Intervention: HF self-management education (attention control)
Number of subjects: 200
Study 28159703 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT-I
Number of subjects: 200
Study 25981329 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Internet-delivered CBT (ICBT)
Number of subjects: 48
Study 25981329 — intervention group
Group type: COMPARATOR
Intervention: Group-delivered CBT (GCBT)
Number of subjects: 48
Study 23876624 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic hip screw (DHS)
Number of subjects: 163
Study 23876624 — intervention group
Group type: COMPARATOR
Intervention: Medoff sliding plate (MSP)
Number of subjects: 163
Study 21601197 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist trigger
Number of subjects: 0
Study 21601197 — intervention group
Group type: COMPARATOR
Intervention: hCG trigger
Number of subjects: 0
Study 21601197 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of hCG to culture media
Number of subjects: 0
Study 19751797 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT)
Number of subjects: 45
Study 19751797 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list (WG)
Number of subjects: 45
Study 16674762 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg diclofenac potassium sachets
Number of subjects: 328
Study 16674762 — intervention group
Group type: COMPARATOR
Intervention: 50 mg diclofenac potassium tablets
Number of subjects: 328
Study 16674762 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 328
Study 16674762 — intervention group
Group type: COMPARATOR
Intervention: Both sachets and tablets
Number of subjects: 328
Study 12661911 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback intervention
Number of subjects: 905
Study 12661911 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation-assisted biofeedback
Number of subjects: 905
Study 12661911 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention controls
Number of subjects: 905
Study 12661911 — intervention group
Group type: COMPARATOR
Intervention: Sham or non-specific behavioral intervention controls
Number of subjects: 905
Study 10708941 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical trials (BNLI)
Number of subjects: 7819
Study 10708941 — intervention group
Group type: COMPARATOR
Intervention: Population-based patients
Number of subjects: 7819
Study 10708941 — intervention group
Group type: EXPERIMENTAL
Intervention: BNLI patients aged 65-74 years
Number of subjects: 7819
Study 10708941 — intervention group
Group type: COMPARATOR
Intervention: Population-based patients aged 65-74 years
Number of subjects: 7819
Study 10708941 — intervention group
Group type: COMPARATOR
Intervention: Both clinical trials and population-based data sets
Number of subjects: 7819
Study 10708941 — intervention group
Group type: EXPERIMENTAL
Intervention: Late stage patients
Number of subjects: 7819
Study 8791970 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride, 20 mg t.d.s.
Number of subjects: 37
Study 1363508 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CYC) with corticosteroids (CS) and plasma exchanges (PE)
Number of subjects: 182
Study 1363508 — intervention group
Group type: COMPARATOR
Intervention: Prednisone and PE
Number of subjects: 182
Study 1363508 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term steroid therapy and PE with anti-viral therapy
Number of subjects: 182
Study 1363508 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-viral agents and PE
Number of subjects: 182
Study 6099915 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg ranitidine at night
Number of subjects: 61
Study 6099915 — intervention group
Group type: COMPARATOR
Intervention: 400 mg cimetidine at night
Number of subjects: 61
Study 30276906 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis Use (CU)
Number of subjects: 37071
Study 30276906 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis Use Disorder (CUD)
Number of subjects: 37071
Study 29066271 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab
Number of subjects: 0
Study 29066271 — intervention group
Group type: COMPARATOR
Intervention: Ustekinumab
Number of subjects: 0
Study 26617284 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketogenic diet (KD)
Number of subjects: 48
Study 26617284 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (CAU)
Number of subjects: 48
Study 26617284 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 48
Study 25499341 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fasudil (30 mg over 30 min)
Number of subjects: 50
Study 25499341 — intervention group
Group type: COMPARATOR
Intervention: Inhaled iloprost (5 μg)
Number of subjects: 50
Study 22521630 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular botulinum toxin A
Number of subjects: 55
Study 22521630 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 55
Study 20053579 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitscan-derived rigid gas permeable contact lens
Number of subjects: 30
Study 20053579 — intervention group
Group type: COMPARATOR
Intervention: Conventional (habitual) contact lens
Number of subjects: 30
Study 18606035 — intervention group
Group type: EXPERIMENTAL
Intervention: Foster care intervention
Number of subjects: 0
Study 18606035 — intervention group
Group type: COMPARATOR
Intervention: Institutional care
Number of subjects: 0
Study 15714898 — intervention group
Group type: COMPARATOR
Intervention: Dichotic listening tests (Fused condition)
Number of subjects: 34
Study 15714898 — intervention group
Group type: COMPARATOR
Intervention: Dichotic listening tests (Non-Fused condition)
Number of subjects: 34
Study 15714898 — intervention group
Group type: COMPARATOR
Intervention: Phonological working memory test
Number of subjects: 34
Study 15714898 — intervention group
Group type: COMPARATOR
Intervention: Phonological processing abilities
Number of subjects: 34
Study 11812750 — intervention group
Group type: EXPERIMENTAL
Intervention: NN2211 (10 microg/kg)
Number of subjects: 11
Study 10382082 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel/ethinyl estradiol (100 micrograms/20 micrograms)
Number of subjects: 173
Study 10382082 — intervention group
Group type: COMPARATOR
Intervention: Norethindrone/ethinyl estradiol (1000 micrograms/20 micrograms)
Number of subjects: 173
Study 8682116 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (atenolol + nifedipine)
Number of subjects: 682
Study 8682116 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 682
Study 8682116 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 682
Study 1899852 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-interferon (7.5 MU/m2 three times weekly for 3 months, then 5 MU/m2 for 3 months, and 2.5 MU/m2 for 6 months)
Number of subjects: 30
Study 1899852 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma-interferon (2 MU/m2 for 6 months)
Number of subjects: 30
Study 1899852 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 30
Study 6538131 — intervention group
Group type: EXPERIMENTAL
Intervention: Phototherapy (Goeckerman or PUVA)
Number of subjects: 7
Study 30252057 — intervention group
Group type: EXPERIMENTAL
Intervention: 11β‐MNTDC (100, 200, 400, and 800 mg)
Number of subjects: 12
Study 30252057 — intervention group
Group type: EXPERIMENTAL
Intervention: 11β‐MNTDC (with food)
Number of subjects: 12
Study 30252057 — intervention group
Group type: EXPERIMENTAL
Intervention: 11β‐MNTDC (200, 400, and 800 mg)
Number of subjects: 12
Study 30252057 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 29176264 — intervention group
Group type: EXPERIMENTAL
Intervention: Chondroitin sulfate 1560 mg/d
Number of subjects: 73
Study 29176264 — intervention group
Group type: COMPARATOR
Intervention: Chondroitin sulfate 260 mg/d (low-dose group, control group)
Number of subjects: 73
Study 29176264 — intervention group
Group type: EXPERIMENTAL
Intervention: Chondroitin sulfate
Number of subjects: 73
Study 26422612 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometric training
Number of subjects: 80
Study 26422612 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional strength training
Number of subjects: 80
Study 26422612 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined training
Number of subjects: 80
Study 26422612 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study 23939595 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT + IE
Number of subjects: 140
Study 23939595 — intervention group
Group type: COMPARATOR
Intervention: CBT + distraction
Number of subjects: 140
Study 22699094 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescent-reported communication in Miami
Number of subjects: 302
Study 22699094 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-reported communication in Miami
Number of subjects: 302
Study 22699094 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-reported communication in Los Angeles
Number of subjects: 302
Study 19066934 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertrophy (H): 4 sets of 10 repetitions in the squat at 75% of 1RM (90 s rest periods)
Number of subjects: 10
Study 19066934 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength (S): 11 sets of three repetitions at 90% of 1RM (5 min rest periods)
Number of subjects: 10
Study 19066934 — intervention group
Group type: EXPERIMENTAL
Intervention: Power (P): 8 sets of 6 repetitions of jump squats at 0% of 1RM (3 min rest periods)
Number of subjects: 10
Study 19066934 — intervention group
Group type: COMPARATOR
Intervention: Rest (R) condition
Number of subjects: 10
Study 17909376 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin
Number of subjects: 0
Study 17909376 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery surgery
Number of subjects: 0
Study 15094439 — intervention group
Group type: EXPERIMENTAL
Intervention: Radio-guided tumour excision after intratumoral injection of 99mTc-nanocolloid
Number of subjects: 65
Study 15094439 — intervention group
Group type: COMPARATOR
Intervention: Wire-directed excision alone (group 2)
Number of subjects: 65
Study 15094439 — intervention group
Group type: EXPERIMENTAL
Intervention: Radio-guided tumour excision
Number of subjects: 65
Study 10980585 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% VO2max exercise bout
Number of subjects: 32
Study 10980585 — intervention group
Group type: EXPERIMENTAL
Intervention: 75% VO2max exercise bout
Number of subjects: 32
Study 10980585 — intervention group
Group type: COMPARATOR
Intervention: Control (no exercise)
Number of subjects: 32
Study 9052605 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovaginal ultrasound (weekly vaginal probe ultrasound scans)
Number of subjects: 92
Study 9052605 — intervention group
Group type: COMPARATOR
Intervention: No vaginal sonography (standard expectant management)
Number of subjects: 92
Study 9052605 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovaginal ultrasound
Number of subjects: 92
Study 9052605 — intervention group
Group type: COMPARATOR
Intervention: No vaginal sonography
Number of subjects: 92
Study 8367670 — intervention group
Group type: EXPERIMENTAL
Intervention: IVER 400 plus DEC 1 mg.kg‐1 (12 patients)
Number of subjects: 49
Study 8367670 — intervention group
Group type: EXPERIMENTAL
Intervention: IVER 400 plus DEC 3 mg.kg‐1 (17 patients)
Number of subjects: 49
Study 8367670 — intervention group
Group type: EXPERIMENTAL
Intervention: IVER 400 plus DEC 6 mg.kg‐1 (10 patients)
Number of subjects: 49
Study 8367670 — intervention group
Group type: COMPARATOR
Intervention: DEC 6 mg.kg‐1 alone (5 patients)
Number of subjects: 49
Study 8367670 — intervention group
Group type: COMPARATOR
Intervention: IVER 400 alone (5 patients)
Number of subjects: 49
Study 3523394 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation training
Number of subjects: 42
Study 3523394 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive coping
Number of subjects: 42
Study 3523394 — intervention group
Group type: COMPARATOR
Intervention: Non-specific placebo control
Number of subjects: 42
Study 2738261 — intervention group
Group type: COMPARATOR
Intervention: Single pulse defibrillation
Number of subjects: 16
Study 2738261 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential pulse defibrillation
Number of subjects: 16
Study 29248992 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalosporin alone (CEPH)
Number of subjects: 126
Study 29248992 — intervention group
Group type: COMPARATOR
Intervention: Cephalosporin + aminoglycoside (CEPH + AG)
Number of subjects: 126
Study 27845859 — intervention group
Group type: COMPARATOR
Intervention: 25-hydroxyvitamin D (25-OHD) levels in women with MetS (35.26 ± 1.61 nmol/l)
Number of subjects: 101
Study 27845859 — intervention group
Group type: COMPARATOR
Intervention: Correlation of 25-OHD levels with waist circumference (WC)
Number of subjects: 101
Study 27845859 — intervention group
Group type: COMPARATOR
Intervention: Correlation of 25-OHD levels with body mass index (BMI)
Number of subjects: 101
Study 27845859 — intervention group
Group type: COMPARATOR
Intervention: Correlation of 25-OHD levels with fat mass index (FMI)
Number of subjects: 101
Study 27845859 — intervention group
Group type: COMPARATOR
Intervention: Correlation of 25-OHD levels with impaired fasting glucose (IFG)
Number of subjects: 101
Study 27845859 — intervention group
Group type: COMPARATOR
Intervention: Percentage of body fat in women with insufficient 25-OHD (39.6%)
Number of subjects: 101
Study 27845859 — intervention group
Group type: COMPARATOR
Intervention: Percentage of body fat in women with deficit of 25-OHD (48.2%)
Number of subjects: 101
Study 27845859 — intervention group
Group type: COMPARATOR
Intervention: Average hand grip strength of participants (27.4 ± 4.7 kg)
Number of subjects: 101
Study 25586212 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 1008
Study 25586212 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 1008
Study 25586212 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine-extended release
Number of subjects: 1008
Study 25586212 — intervention group
Group type: EXPERIMENTAL
Intervention: All medications
Number of subjects: 1008
Study 23852365 — intervention group
Group type: EXPERIMENTAL
Intervention: Real rTMS (1 Hz, 600 pulses per session, 90% resting motor threshold)
Number of subjects: 0
Study 23852365 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0
Study 21565338 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoendoscopic single-site surgery (LESS)
Number of subjects: 60
Study 21565338 — intervention group
Group type: COMPARATOR
Intervention: Conventional multiaccess laparoscopy (LPS)
Number of subjects: 60
Study 19300267 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate-remifentanil
Number of subjects: 60
Study 19300267 — intervention group
Group type: COMPARATOR
Intervention: Propofol-remifentanil
Number of subjects: 60
Study 16790650 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.125% and sufentanil 0.75 microg/mL with epinephrine 1:800,000
Number of subjects: 70